Cargando…

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials

BACKGROUND: Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD). To further explore the long-term efficacy of tralokinumab for AD, a pooled analysis of these trials was conducted. METHODS: ECZ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simpson, Eric L., Pink, Andrew E., Blauvelt, Andrew, Gooderham, Melinda, Armstrong, April W., Worm, Margitta, Katoh, Norito, Peris, Ketty, Puig, Luis, Barbarot, Sébastien, Mark, Thomas, Steffensen, Louise Abildgaard, Tindberg, Ann-Marie, Wollenberg, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570233/ https://www.ncbi.nlm.nih.gov/pubmed/37682422 http://dx.doi.org/10.1007/s40257-023-00806-3

Ejemplares similares

Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
por: Silverberg, Jonathan I., et al.
Publicado: (2022)

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)
por: Wollenberg, A., et al.
Publicado: (2020)

Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2023)

Population Pharmacokinetics of Tralokinumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
por: Soehoel, Anders, et al.
Publicado: (2022)

Atopic dermatitis treated with tralokinumab and upadacitinib combination therapy: A case report
por: Lansang, Rafael Paolo, et al.
Publicado: (2023)

Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
por: Kelly, Katherine A, et al.
Publicado: (2022)

Real-World Experience with Tralokinumab in a Patient with Recalcitrant Atopic Dermatitis: A Case Report
por: Moennig, Eva, et al.
Publicado: (2022)

Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis: A Secondary Analysis
por: Merola, Joseph F., et al.
Publicado: (2023)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

Skin Barrier and Inflammation Genes Associated with Atopic Dermatitis are Regulated by Interleukin-13 and Modulated by Tralokinumab In vitro
por: TOLLENAERE, Maxim A. X., et al.
Publicado: (2021)

Atopic dermatitis and food allergy: when and how to test?
por: Worm, Margitta
Publicado: (2011)

Atopic Dermatitis: Identification and Management of Complicating Factors
por: Tamagawa-Mineoka, Risa, et al.
Publicado: (2020)

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
por: De Greef, Axel, et al.
Publicado: (2023)

Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials
por: Zhao, Dan-Jie, et al.
Publicado: (2023)

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials
por: Wollenberg, Andreas, et al.
Publicado: (2023)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Targeting IL-4 for the Treatment of Atopic Dermatitis
por: Chiricozzi, Andrea, et al.
Publicado: (2020)

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
por: Eshtiaghi, Panteha, et al.
Publicado: (2018)

Treatment of atopic dermatitis with pimecrolimus – impact on quality of life
por: Lee, Hae-Hyuk, et al.
Publicado: (2007)

Overview of Atopic Dermatitis in Different Ethnic Groups
por: Chiricozzi, Andrea, et al.
Publicado: (2023)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial
por: Silverberg, J.I., et al.
Publicado: (2021)

Novel Therapeutic Strategies in the Topical Treatment of Atopic Dermatitis
por: Pinto, Lorenzo Maria, et al.
Publicado: (2022)

Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
por: de Bruin‐Weller, M., et al.
Publicado: (2020)

Exploratory analyses of biomarkers in blood and stratum corneum in patients with atopic dermatitis
por: Maruyama, Ayano, et al.
Publicado: (2022)

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin–Induced Adverse Ocular Events—Incidence, Etiology, and Management
por: Mickevicius, Tomas, et al.
Publicado: (2023)

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials
por: Katoh, Norito, et al.
Publicado: (2022)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
por: Paller, Amy S., et al.
Publicado: (2022)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Correction to: Tralokinumab: First Approval
por: Duggan, Sean
Publicado: (2021)

Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids
por: Silverberg, Jonathan I., et al.
Publicado: (2023)

Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2021)

Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
por: Katoh, Norito, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_crev429g7v7skpft9p2u1mr2vo